• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » InVivo steady on in-line Q4, FY2016 earnings report

InVivo steady on in-line Q4, FY2016 earnings report

March 10, 2017 By Fink Densford

InVivo

Shares in InVivo Therapeutics (NSDQ:NVIV) rose slightly today after the medical device developer posted 4th quarter and full year 2016 earnings that mostly fell in line with consensus on Wall Street.

The Cambridge, Mass.-based company posted losses of $5.4 million, or 17¢ per share for the 3 months ended December 31, with losses growing 14.8% while losses per share stayed steady.

Adjusted to exclude 1-time items, losses were $6.8 million, or 21¢ per share, slightly higher than expectations on Wall Street of 19¢.

For the full year, InVivo Therapeutics posted losses of $23.4 million, or 76¢ per share, with losses and losses per share shrinking 29.6% and 39.7%, respectively, compared with the prior year.

Non-GAAP losses per share were 78¢ for the year, down 8.2% from last year and in line with expectations on The Street.

“2016 was a year marked by meaningful and significant progress. In 2016, we: received approval for converting the Neuro-Spinal Scaffold pilot study to the pivotal Inspire study; received approval to initiate the Inspire study in Canada (1st global step for InVivo); added 13 new clinical sites, including our first ex-U.S. sites (both in Canada); enrolled 7 new patients, with 3 of those patients achieving the primary endpoint of conversion to partial paralysis by 6 months post-injury; continued our spinal cord injury (SCI) thought leadership by attending and presenting at international conferences, where we presented 13 scientific abstracts to renowned leaders within the neurosurgical, neuroscience, and SCI communities; raised $32 million (gross), which is the company’s largest fund raising to date; successfully developed a preclinical prototype of the TrailMaker for the chronic spinal cord injury market and filed two patent applications; garnered unique media coverage about InVivo and the Neuro-Spinal Scaffold in 18 widely-read outlets resulting in nearly 30 million media impressions; and continued to make great strides in strengthening our research and intellectual property portfolio,” CEO Mark Perrin said in a prepared statement.

Shares in InVivo closed up 1.3% at $4.

Filed Under: Business/Financial News, MassDevice Earnings Roundup Tagged With: InVivo Therapeutics

More recent news

  • Medtronic partners with IRCAD on Hugo, Affera surgical training
  • 23andMe co-founder wins bid to take back control of company
  • Neurent Medical opens new manufacturing facility in Ireland
  • Brain Navi wins FDA nod for neurosurgical robot
  • Adona Medical completes enrollment in first-in-human interatrial shunt trial

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy